Acorda Therapeutics (ACORQ) 10-Q2023 Q1 Quarterly report

Filed: 11 May 23, 5:09pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: API, argument, bottle, breach, capsule, carton, Chance, clinical, comprehensive, directly, disregarded, dividend, earned, excipient, expedient, favor, fixed, found, furniture, Hangzhou, hindsight, hold, holding, illegal, illegally, inflation, ingredient, leasehold, leveraged, member, MSA, NMPA, objective, opening, orderly, overpaid, paper, Patheon, pattern, petition, practical, pre, problem, quantity, render, renewed, request, requested, restitution, retrospective, se, solved, Southern, study, temporary, transition, transparency, unenforceable, unlawful, violation

Removed: absent, absorption, added, advance, affiliate, AllianceRx, allocating, allocation, American, AmeriSource, amounted, appeal, apply, Arzneimittel, ASD, assigned, assignment, assistance, assumption, attrition, back, bank, baseline, Bergen, book, borne, borrower, brain, bridge, broker, building, cancelled, candidate, capable, Center, challenge, characterized, claim, claimed, clarify, classify, closely, collaboratively, collectively, commitment, complexity, composition, conducted, consistently, copay, correct, covering, creating, criterion, daily, dalmfapridine, decide, deducting, delay, determination, difficulty, directed, discarded, disclose, discontinued, dismissed, disorder, dispense, disposal, disrupt, disruptive, distributed, diversity, divest, divestiture, dopamine, DRI, dryer, easier, EC, education, educator, electronic, eligibility, eliminate, enable, enacted, enforce, enhancing, EP, exchanged, execution, expand, expedite, expensed, experiencing, expire, expiring, extensive, face, fall, federally, finalizing, force, forecasted, formality, fourteen, funded, German, goodwill, gradual, greater, hand, Hedging, high, hire, hub, ill, implemented, importance, improvement, inadmissible, increased, incurring, individual, inhaler, initiate, installation, institutional, instrument, intraperiod, inventive, lacked, landlord, larger, line, list, listed, loan, located, lose, low, LSRC, Luke, MA, MAA, maintained, making, manufactured, measuring, Minnesota, movement, muscle, navigate, NDA, neurodegenerative, newly, novelty, nurse, NY, opposed, Opposition, originally, origination, par, paragraph, partial, past, paying, preliminary, prescribing, Prime, proceed, producing, program, project, proper, prospectively, protected, qualification, ratiopharm, raw, recently, recognizing, Refer, referred, refile, refinance, reform, reimbursement, released, reliant, remained, renovate, renovation, responsible, resulted, return, reviewing, Rush, sample, scrapped, SEC, seek, separated, shift, short, Simplifying, situated, size, sooner, speed, St, STADA, stakeholder, step, strategic, support, supported, sustained, Technical, Teva, therapeutic, thereto, training, transferred, treat, trial, Troubled, ultimately, United, unnamed, upheld, usage, valid, variability, verification, vigorously, Vintage, virtual, warehousing, wide, working, wrote

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ACORQ transcripts

ACORQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Acorda Therapeutics, Inc. (the “Company”) for the fiscal quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael Gesser, Chief Financial Officer and Treasurer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Michael Gesser

Michael Gesser

Chief Financial Officer and Treasurer

(Principal Financial Officer)

May 11, 2023

[A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Acorda Therapeutics, Inc. and will be retained by Acorda Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.]